Table 3. Antigen specificity and HLA... | American Society of Hematology

Table 3.

Antigen specificity and HLA restriction of IFN-γ production by bcr-abl-specific CD4⁺ T-lymphocyte clones in response to CML-derived mature DCs

Clone	DC donor, patient no.	HLA-DRB1	mAb added	IFN-γ production, pg/mL^3-150
MY-1	Autologous	^3-1500901/1406	None	< 10
	b3a2 CML, no. 1	^3-1500901/1201	None	636 ± 85
			Anti-HLA class I	652 ± 68
			Anti-HLA-DR	133 ± 18
	b3a2 CML, no. 2	^3-1500901/1001	None	706 ± 103
			Anti-HLA class I	721 ± 58
			Anti-HLA-DR	159 ± 21
	b3a2 CML, no. 3^3-151	^3-1500901/1502	None	87 ± 10
	b3a2 CML, no. 4	^3-1500405/0803	None	52 ± 17
	b3a2 CML, no. 5	^3-1500803/1405	None	62 ± 6
	b2a2 CML, no. 6	^3-1500901/1302	None	51 ± 9
	b2a2 CML, no. 7	^3-1500901/1101	None	< 10
	b2a2 CML, no. 8	^3-1500403/1502	None	< 10
TO-1	Autologous	^3-1500901/0405	None	36 ± 14
	b3a2 CML, no. 1	^3-1500901/1201	None	821 ± 79
			Anti-HLA class I	801 ± 51
			Anti-HLA-DR	175 ± 28
	b3a2 CML, no. 2	^3-1500901/1001	None	688 ± 46
			Anti-HLA class I	672 ± 56
			Anti-HLA-DR	128 ± 13
	b3a2 CML, no. 3^3-151	^3-1500901/1502	None	66 ± 10
	b3a2 CML, no. 4	^3-1500405/0803	None	52 ± 4
	b3a2 CML, no. 5	^3-1500803/1405	None	< 10
	b2a2 CML, no. 6	^3-1500901/1302	None	< 10
	b2a2 CML, no. 7	^3-1500901/1101	None	43 ± 4
	b2a2 CML, no. 8	^3-1500403/1502	None	< 10

Clone	DC donor, patient no.	HLA-DRB1	mAb added	IFN-γ production, pg/mL^3-150
MY-1	Autologous	^3-1500901/1406	None	< 10
	b3a2 CML, no. 1	^3-1500901/1201	None	636 ± 85
			Anti-HLA class I	652 ± 68
			Anti-HLA-DR	133 ± 18
	b3a2 CML, no. 2	^3-1500901/1001	None	706 ± 103
			Anti-HLA class I	721 ± 58
			Anti-HLA-DR	159 ± 21
	b3a2 CML, no. 3^3-151	^3-1500901/1502	None	87 ± 10
	b3a2 CML, no. 4	^3-1500405/0803	None	52 ± 17
	b3a2 CML, no. 5	^3-1500803/1405	None	62 ± 6
	b2a2 CML, no. 6	^3-1500901/1302	None	51 ± 9
	b2a2 CML, no. 7	^3-1500901/1101	None	< 10
	b2a2 CML, no. 8	^3-1500403/1502	None	< 10
TO-1	Autologous	^3-1500901/0405	None	36 ± 14
	b3a2 CML, no. 1	^3-1500901/1201	None	821 ± 79
			Anti-HLA class I	801 ± 51
			Anti-HLA-DR	175 ± 28
	b3a2 CML, no. 2	^3-1500901/1001	None	688 ± 46
			Anti-HLA class I	672 ± 56
			Anti-HLA-DR	128 ± 13
	b3a2 CML, no. 3^3-151	^3-1500901/1502	None	66 ± 10
	b3a2 CML, no. 4	^3-1500405/0803	None	52 ± 4
	b3a2 CML, no. 5	^3-1500803/1405	None	< 10
	b2a2 CML, no. 6	^3-1500901/1302	None	< 10
	b2a2 CML, no. 7	^3-1500901/1101	None	43 ± 4
	b2a2 CML, no. 8	^3-1500403/1502	None	< 10

F3-150

IFN-γ production by MY-1 and TO-1 in the presence of autologous mature DCs and mature DCs derived from various patients with CML was determined by ELISA. The results shown represent the means ± SDs of triplicate experiments.

F3-151

CML patient no. 3 was in complete cytogenetic remission.

View Large

This Feature Is Available To Subscribers Only